Why Inovio Pharmaceuticals Stock Sank in October
According to S&P Global Market Intelligence, shares of the DNA vaccine maker Inovio Pharmaceuticals (NASDAQ: INO) shed 8% of their value last month. On the bright side, this high single-digit decline wasn't the result of a negative clinical or regulatory event specific to the company.
Inovio's shares, by contrast, appear to have simply followed the broader biotech industry lower last month, evinced by the poor performance of the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) in October.
Source: Fool.com
Inovio Pharma Stock
€0.53
-2.240%
With 6 Sell predictions and only 2 Buy predictions the community sentiment for Inovio Pharma is rather negative.
However, we have a potential of 1967.67% for Inovio Pharma as the target price of 11 € is above the current price of 0.53 €.
